ReviewJAMA2023
Diabetic Foot Ulcers: A Review.
Review in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 833 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Interplay of Acute-to-Chronic Glycemic Ratio With Other Biomarkers in Diabetic Foot Ulcers: An Effect is Not Related to the Therapeutic Remedies
The Role of Muscle Elastic Properties of Extrinsic Foot Muscles, Muscle Oxygenation and Plantar Pressure Change in Determining Diabetic Foot Ulcer Risk
Efficacy and Safety of a Carbopol® 940 Hydrogel Functionalized With Plasma-Activated Water (PAW) in the Treatment of Chronic Wounds: A Randomized Controlled Trial
Nutritional Status in Adults With Diabetic Foot in an Outpatient Wound Clinic: A Feasibility and Pilot Study
Who cites it
833 citing papers in PubMed, 5 syntheses or guidelines pooled it, 1,186 citations in OpenAlex.
- Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis.International wound journal · 2026Pooled it
- Diabetic Foot Ulceration in Dialysis-Dependent End-Stage Kidney Disease: A Systematic Review of Epidemiology, Clinical Outcomes and Mortality Risk.Diabetes/metabolism research and reviews · 2026Pooled it
- Risk Factors for Foot-Related Hospitalisations in Adults With and Without Diabetes: A Systematic Review.Journal of foot and ankle research · 2026Pooled it
- Topical therapies for diabetic foot ulcers: a systematic review and network meta-analysis.BMJ open diabetes research & care · 2026Pooled it
- Predictors of Complications and Recurrence After Pressure Injury Reconstruction in Spinal Cord Injury: A Systematic Review and Meta-Analysis.International wound journal · 2026Pooled it
- A Composite Ovine Forestomach Matrix and Hyaluronic Acid CAMP for the Treatment of Full Thickness Wounds of the Foot in People With Diabetes: A Randomized Controlled Trial.International wound journal · 2026Trial
- Emerging bioactive microneedle platforms for disease management: From cutaneous disorders to systemic therapeutics.Bioactive materials · 2026Review
- Post-translational modification-regulating biomaterials for regeneration.Bioactive materials · 2026Review
- miR‑222‑3p inhibits diabetic skin wound healing by targeting APLN.International journal of molecular medicine · 2026Article
- Sirt1 transgene delivery improves diabetes-impaired wound healing.Bioactive materials · 2026Article
- The burden of diabetic foot ulcers in a multi-ethnic Asian cohort.Diabetic medicine : a journal of the British Diabetic Association · 2026Observational
- Mild photothermal-responsive hydrogel with HBioactive materials · 2026Article
- Hair Follicle Stem Cells: Emerging Physiology and Therapeutic Applications.Stem cell reviews and reports · 2026Review
- Cortistatin antagonizes Piezo1-STING axis and facilitates mitochondrial homeostasis of keratinocytes by attenuating AGEs accumulation in diabetic ulcers.Cell death and differentiation · 2026Article
- DianDao San Promotes CSU Wound Healing by Inhibiting TNF/NF-κB Pathway.Applied biochemistry and biotechnology · 2026Article
- Hydrogel microneedles loaded with engineered extracellular vesicles accelerate diabetic wound healing by promoting angiogenesis and modulating macrophage polarization.Materials today. Bio · 2026Article
- In Situ Genetic Engineering Facilitates MMP-9-Responsive TIMP1 Release Through Proteolytic Cleavage to Boost Diabetic Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Preclinical Efficacy of Recombinant Human Platelet-Derived Growth Factor-BB in Experimental Diabetic Wound Healing: A Systematic Review and Meta-Analysis of Animal Studies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Intralesional Epidermal Growth Factor and Its Association with Reamputation and Level-Up Amputation in Diabetic Foot Patients with Post-Amputation Flap Necrosis: Clinical Outcomes and Macrophage Dynamics.Medicina (Kaunas, Lithuania) · 2026Observational
- Thalamic neuronal and bioenergetic function in painful diabetic peripheral neuropathy: a dual magnetic resonance spectroscopy study.Diabetologia · 2026Article
773 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
Importance: Approximately 18.6 million people worldwide are affected by a diabetic foot ulcer each year, including 1.6 million people in the United States. These ulcers precede 80% of lower extremity amputations among people diagnosed with diabetes and are associated with an increased risk of death. Observations: Neurological, vascular, and biomechanical factors contribute to diabetic foot ulceration. Approximately 50% to 60% of ulcers become infected, and about 20% of moderate to severe infections lead to lower extremity amputations. The 5-year mortality rate for individuals with a diabetic foot ulcer is approximately 30%, exceeding 70% for those with a major amputation. The mortality rate for people with diabetic foot ulcers is 231 deaths per 1000 person-years, compared with 182 deaths per 1000 person-years in people with diabetes without foot ulcers. People who are Black, Hispanic, or Native American and people with low socioeconomic status have higher rates of diabetic foot ulcer and subsequent amputation compared with White people. Classifying ulcers based on the degree of tissue loss, ischemia, and infection can help identify risk of limb-threatening disease. Several interventions reduce risk of ulcers compared with usual care, such as pressure-relieving footwear (13.3% vs 25.4%; relative risk, 0.49; 95% CI, 0.28-0.84), foot skin measurements with off-loading when hot spots (ie, greater than 2 °C difference between the affected foot and the unaffected foot) are found (18.7% vs 30.8%; relative risk, 0.51; 95% CI, 0.31-0.84), and treatment of preulcer signs. Surgical debridement, reducing pressure from weight bearing on the ulcer, and treating lower extremity ischemia and foot infection are first-line therapies for diabetic foot ulcers. Randomized clinical trials support treatments to accelerate wound healing and culture-directed oral antibiotics for localized osteomyelitis. Multidisciplinary care, typically consisting of podiatrists, infectious disease specialists, and vascular surgeons, in close collaboration with primary care clinicians, is associated with lower major amputation rates relative to usual care (3.2% vs 4.4%; odds ratio, 0.40; 95% CI, 0.32-0.51). Approximately 30% to 40% of diabetic foot ulcers heal at 12 weeks, and recurrence after healing is estimated to be 42% at 1 year and 65% at 5 years. Conclusions and Relevance: Diabetic foot ulcers affect approximately 18.6 million people worldwide each year and are associated with increased rates of amputation and death. Surgical debridement, reducing pressure from weight bearing, treating lower extremity ischemia and foot infection, and early referral for multidisciplinary care are first-line therapies for diabetic foot ulcers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.